Resona Asset Management Co. Ltd. Sells 2,868 Shares of Becton, Dickinson and Company $BDX

Resona Asset Management Co. Ltd. decreased its stake in Becton, Dickinson and Company (NYSE:BDX) by 2.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 102,418 shares of the medical instruments supplier’s stock after selling 2,868 shares during the period. Resona Asset Management Co. Ltd.’s holdings in Becton, Dickinson and Company were worth $19,090,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. SOA Wealth Advisors LLC. grew its stake in Becton, Dickinson and Company by 256.8% in the third quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 95 shares in the last quarter. Bell Investment Advisors Inc boosted its holdings in shares of Becton, Dickinson and Company by 474.1% in the 2nd quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 128 shares during the last quarter. Grey Fox Wealth Advisors LLC bought a new position in shares of Becton, Dickinson and Company in the third quarter valued at $32,000. Bank of Jackson Hole Trust increased its holdings in Becton, Dickinson and Company by 85.6% during the second quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock worth $35,000 after buying an additional 95 shares during the last quarter. Finally, CVA Family Office LLC raised its position in Becton, Dickinson and Company by 79.5% during the second quarter. CVA Family Office LLC now owns 219 shares of the medical instruments supplier’s stock worth $38,000 after acquiring an additional 97 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on BDX shares. Morgan Stanley boosted their price objective on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 2nd. Weiss Ratings reissued a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday, October 8th. Wall Street Zen cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Stifel Nicolaus boosted their target price on Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Finally, Piper Sandler dropped their price target on Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating on the stock in a research note on Friday, November 7th. Four investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, Becton, Dickinson and Company currently has an average rating of “Hold” and a consensus target price of $207.64.

Insider Activity

In other news, Director Bertram L. Scott sold 217 shares of Becton, Dickinson and Company stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $176.58, for a total value of $38,317.86. Following the completion of the sale, the director directly owned 35,816 shares in the company, valued at approximately $6,324,389.28. The trade was a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael David Garrison sold 1,610 shares of the stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the sale, the executive vice president directly owned 12,095 shares in the company, valued at $2,509,228.70. This represents a 11.75% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 2,662 shares of company stock valued at $535,246 in the last quarter. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $201.84 on Friday. The firm has a market cap of $57.51 billion, a P/E ratio of 34.62, a price-to-earnings-growth ratio of 2.23 and a beta of 0.23. The business’s 50 day moving average is $197.40 and its 200-day moving average is $190.42. The company has a current ratio of 1.11, a quick ratio of 0.64 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 1-year low of $162.29 and a 1-year high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $3.96 EPS for the quarter, beating analysts’ consensus estimates of $3.92 by $0.04. The firm had revenue of $5.89 billion for the quarter, compared to analyst estimates of $5.91 billion. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The company’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same period in the prior year, the firm posted $3.81 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. Equities research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, December 31st. Investors of record on Monday, December 8th were given a dividend of $1.05 per share. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. This represents a $4.20 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date of this dividend was Monday, December 8th. Becton, Dickinson and Company’s payout ratio is 72.04%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.